{"entity":{"id":"da-roche","kind":"company","name":"Roche","aka":[],"tldr":"Roche is developing trontinemab and has studied prasinezumab against alpha-synuclein.","summary":"Map node for Brainshuttle amyloid and synuclein antibody programmes. Pipeline status is not a recommendation to use an unapproved medicine.","asOf":"2026-09-21","links":[{"label":"Roche","url":"https://www.roche.com/"}],"tags":["dementia-atlas"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["da-trontinemab","da-prasinezumab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["da-trial-trontier","da-trial-prasinezumab"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Basel","country":"CH","companyType":"pharma","website":"https://www.roche.com/","investors":[],"funding":[]},"route":"/companies/da-roche/","neighbours":{"drug":[{"id":"da-prasinezumab","kind":"drug","name":"Prasinezumab","route":"/drugs/da-prasinezumab/"},{"id":"da-trontinemab","kind":"drug","name":"Trontinemab","route":"/drugs/da-trontinemab/"}],"trial":[{"id":"da-trial-prasinezumab","kind":"trial","name":"Prasinezumab (PASADENA / related)","route":"/trials/da-trial-prasinezumab/"},{"id":"da-trial-trontier","kind":"trial","name":"TRONTIER 2 (trontinemab Phase 3)","route":"/trials/da-trial-trontier/"}],"cancer":[{"id":"alzheimers-disease","kind":"cancer","name":"Alzheimer’s disease","route":"/diagnoses/alzheimers-disease/"}]}}